Call for Abstract
9th International Virology Congress and Expo, will be organized around the theme “An Insight on Advances in Virology and Infectious Diseases and its significance”
Virology Congress 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Virology Congress 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
The Global Virology Market has a Turn Over of $1485.02 million in 2013 and is expected to reach $1932.8 million by 2018; at a CAGR of 5.6% from 2013 to 2018.Spain is one of the major countries where the market is improving every year as researchers are showing greater interest in microbiological studies. Viral evolution is a subfield of evolutionary biology and virology that is specifically concerned with the evolution of viruses. Many viruses, in particular RNA viruses, have short generation times and relatively high mutation rates (on the order of one point mutation or more per genome per round of replication for RNA viruses). Virus Genomes are very small and they are incredibly diverse and subject to rapid genetic change.
- Track 1-1Viral Genomics and Proteomics
- Track 1-2Cellular Factors Affecting Viral Replication and Pathogenicity
- Track 1-3Viral Tropism and Transmission
- Track 1-4Viral Replication Cycle
- Track 1-5Vaccine development
Zika virus is a member of the virus family Flaviviridae and the genus Flavivirus. It is spread by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus The infection, known as Zika fever or Zika virus disease, often causes no or only mild symptoms, similar to a very mild form of dengue fever. While there is no specific treatment, paracetamol (acetaminophen) and rest may help with the symptoms.As of 2016, the illness cannot be prevented by medications or vaccines. Zika can also spread from a pregnant woman to her foetus. This can result in microcephaly, severe brain malformations, and other birth defects. Zika infections in adults may rarely result in Guillain–Barré syndrome.
Ebola virus disease (EVD), also known as Ebola haemorrhagic fever (EHF) or simply Ebola, is a viral haemorrhagic fever of humans and other primates caused by Ebola viruses. Signs and symptoms typically start between two days and three weeks after contracting the virus with a fever, sore throat, muscular pain, and headaches. Then, vomiting, diarrhoea and rash usually follow, along with decreased function of the liver and kidneys. At this time some people begin to bleed both internally and externally.
- Track 2-1Symptoms AND Diagnosis
- Track 2-2Transmission
- Track 2-3Treatment and Prevention
- Track 2-4Complications of Zika and Ebola virus disease
- Track 2-5Pathogenesis
- Track 2-6Vaccine development and Research
- Track 2-7Epidemiology
Viral diseases/infections of the oral cavity, oral mucosa and perioral regions are generally encountered by dentists and have not received the required recognition until recently and viruses are both - ulcer genic and the tumorigenic agents of human oral cavity. The plethora of mammalian viruses in the lesions seen in periodontitis proposes that viruses play a significant role in oral diseases than earlier recognized. One of the most crucial target of oral microbiology in future would be to arbitrate the diversity, magnitude, frequency, pathogenicity, treatment and prognosis of oral viruses and the infections they cause.
- Track 3-1Types of Oral Infections
- Track 3-2Differential diagnosis of viral Oral infections
- Track 3-3Oral infection by herpes simplex Virus
- Track 3-4Oral infections by cytomegalovirus
- Track 3-5Hand, Foot & Mouth disease
- Track 3-6Oral infection by Wart- HPV ( Human papillomavirus )
- Track 3-7Oral infections by Coxsackie virus (cox)
- Track 3-8Oral infections by Measles , Mums and Rubella virus ( MMR )
- Track 3-9Treatment
The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast periods to reach $14.1 billion in 2016.
Viral entry is the earliest stage of infection in the viral life cycle, as the virus comes into contact with the host cell and introduces viral material into the cell. The human immunodeficiency virus is a lentivirus(s subgroup of viruses) that causes HIV infection and acquired immunodeficiency syndrome. HIV diagnosis is done by testing your blood or saliva for antibodies to the virus. HIV/AIDS clinical trials are research studies done to look at new ways to prevent, detect, or treat HIV/AIDS. Clinical Trials are the fastest way to determine if new medical approaches to HIV/AIDS are safe and effective in people.
- Track 4-1RNA silencing in virology
- Track 4-2Swine flu outbreak,Prevention & Treatment
- Track 4-3Corona Viruses
- Track 4-4Severe acute respiratory syndrome
- Track 4-5Polio virus
- Track 4-6Oncovirus
- Track 4-7Virus Receptors & Viral Entry
- Track 4-8Herpes & Pox Viruses
- Track 4-9Filoviruses-Ebola virus & Westnile Viruses
- Track 4-10Viral meningitis
- Track 4-11Influenza Viruses
- Track 4-12Clinical Viral Diagnostics
- Track 4-13Vector and Blood born Diseases & Molecular Diagnosis of CNS Viral Infections
Due to the widespread infection of HCV and demand for these improved therapies, multiple estimates forecast the global market for HCV treatment will reach $20 billion annually by the end of the decade.
- Track 5-1Hepatitis A
- Track 5-2Hepatitis B
- Track 5-3Hepatitis C
- Track 5-4Hepatitis D
- Track 5-5Hepatitis E
- Track 5-6Epidemiology hepatitis
The agricultural inoculants market, in terms of value, is projected to reach $398.56 million by 2019, at a CAGR of around 9.5% from 2014.
The epidemiology of plant virus diseases concerns the cyclical development of virus diseases within plant populations in time and space. Tobacco mosaic virus (TMV) is a positive-sense single stranded RNA virus that infects a wide range of plants, especially tobacco and other members of the family Solanaceae. Mycology is the branch of biology which deals with the study of fungi, including their genetic and biochemical properties, their taxonomy and their use to humans as a source for tinder, medicine, wine and entheogens, as well as their dangers, such as poisoning or infection.
- Track 6-1Plant virus epidemiology, ecology and evolution
- Track 6-2Transmission of plant viruses
- Track 6-3Translation of plant viral proteins
- Track 6-4Tobacco Mosaic Virus
- Track 6-5Bymovirus
- Track 6-6Geminivirus
- Track 6-7Phycodnaviridae
- Track 6-8Tobamovirus
- Track 6-9Mycology
"Clinical Trial Management System (CTMS) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019", states that the global clinical trial management systems market, which was worth US$844 million in 2013, will grow at a CAGR of 14% between 2013 and 2019 to acquire net worth of an estimated US$1,848.5 million by 2019.
Clinical virology is a branch of medicine which comprises in disconnecting and/or in portraying one or a few infections in charge of some human pathologies by different immediate or backhanded methods (cell Cultures, serologies, biochemistry, molecular biology). It additionally comprises in demonstrating the nonattendance of resistance of viruses in treatment antiviral by viral genome sequencing to adjust antiviral therapeutics, best case scenario. Neurovirology is an interdisciplinary field which represents a melding of clinical neuroscience, virology, immunology, and molecular biology. The main focus of the field is to study viruses capable of infecting the nervous system.
- Track 7-1Diagnostic methods in virology
- Track 7-2Mechanism of Viral entry into the nervous system
- Track 7-3Vector and Blood borne Diseases & Molecular Diagnosis of CNS Viral Infections
- Track 7-4Aging and Metabolic Syndromes of Neurologic Disorders by Viruses
- Track 7-5Tools used for diagnosing neuroviral infections
EAC predicts that the viral market will grow from its 2011 global size of $4.2 billion to $6.9 billion in 2016, representing a compound annual growth rate (CAGR) of 10.6%
Viral infections are probably the most important cause of childhood morbidity and mortality in the world. In many developing countries in South East Asia and the Western Pacific, priority health problems include acute respiratory infections, acute diarrhoeas and arboviral infections.
- Track 8-1Hand-foot-and-mouth (HFM) disease
- Track 8-2Herpangina
- Track 8-3Myocarditis
- Track 8-4Aseptic meningitis
- Track 8-5Pleurodynia
The Global Microbiology Market at an estimated $1485.02 million in 2013 and are expected to reach $1932.8 million by 2018, at a CAGR of 5.6% from 2013 to 2018.
Antiviral drugs are a class of medication used specifically for treating viral infections. DNA immunization is a novel technique used to efficiently stimulate humoral and cellular immune responses to protein antigens. Viral vaccines contain either inactivated viruses or attenuated viruses. Oncolytic virotherapy is an emerging treatment modality which uses replication competent viruses to destroy cancers.
- Track 9-1Oncolytic virotherapy
- Track 9-2Viral immunotherapy
- Track 9-3DNA Immunization
- Track 9-4Antigen presenting cell-targeted therapy
- Track 9-5Antiviral drugs and adjuvants
The global Cancer/Tumour Profiling Market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018.
Viral Gastroenteritis is an inflammation of the stomach and intestines caused by one of any number of viruses. It is also known as the stomach flu. Hepatocellular carcinoma is the most common type of liver cancer. Human Papillomaviruses (HPVs) are the causative agents of a number of human tumours, including cervical cancer, which is the major cause of cancer related death in women in many parts of the developing world.
- Track 10-1Viral Gastroenteritis
- Track 10-2SV40 and Polyomavirus
- Track 10-3Retroviruses
- Track 10-4Clinical immunology
- Track 10-5Clinical immunology
- Track 10-6Mammalian tumour Viruses
The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.
Immunotherapy can be defined as the Treatment to stimulate or restore the ability of the immune (defence) system to fight infection and disease. Biological therapy is thus any form of treatment that uses the body's natural abilities that constitute the immune system to fight infection and disease or to protect the body from some of the side effects of treatment. Chemotherapy and radiation therapy are two of the most effective treatment approaches for cancer.
- Track 11-1Chemotherapy
- Track 11-2Radiotherapy
- Track 11-3Cellular immunotherapy
- Track 11-4Cancer immunotherapy
- Track 11-5Antibody therapy
- Track 11-6Cytokine therapy
- Track 11-7Immune system stimulation
- Track 11-8Acquired resistance
The global animal healthcare market was valued at USD 27,861.2 million in 2013 and is expected to grow at a CAGR of 7.1% from 2014 to 2019, to reach an estimated value of USD 41,929.1 million in 2019.
Veterinary virology is the study of viruses in animals. It is an important branch of veterinary medicine. An Emerging virus is a term applied to a newly discovered virus, one that is increasing in incidence or with the potential to increase in incidence. Zoonotic diseases/infections are those which can be naturally transmissible from vertebrate animals to humans. Transmissible spongiform encephalopathies (TSEs), also known as prion diseases represent a group of conditions that affect the nervous system in humans and animals.
- Track 12-1Pestiviruses
- Track 12-2Arteriviruses
- Track 12-3Hantavirus
- Track 12-4Toroviruses
- Track 12-5Avian influenza
- Track 12-6Circoviruses
- Track 12-7Flaviviruses
- Track 12-8Paramyxoviruses
he vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%.
Major point driving growth of vaccine technology market incorporate rising pervasiveness of infections, increasing government activities for growing immunization over the globe, expanding organization interests in immunization improvement, and rising activities by non-government associations for immunizations. Clinical trials are research studies that investigate whether a medicinal methodology, treatment, or device is safe and effective for humans.
2nd World Congress on Infectious Diseases August 25-27, 2016 Philadelphia, USA; International Infectious Diseases & Diagnostic Microbiology Conference , October3-5, 2016; 2nd International Conference on Retroviruses & Novel Drugs June 30-July 01, 2016 Cape Town, South Africa; International Conference on Cancer Immunology and Immunotherapy July 28-30, 2016 Melbourne, Australia;4th International conference on Clinical Microbiology & Microbial Genomics, Oct 05-07, Philadelphia, USA; 32nd Clinical VirologySymposium,May 19-22,2016 Florida, USA; IV International Clinical Virology Symposium and Advances in Vaccines Oct 24-26,2016 Argentina;10th Asia-Pacific Congress of Medical Virology,Oct 15-18,2016 Taiwan; 26th Annual Meeting of the Society for Virology,April 6-9,2016 Germany; 14th International Symposium onNeuroVirology,2016, Canada. International Society for Antiviral Research (ISAR), International Society for NeuroVirology, European Society for Clinical Virology (ESCV), Swedish Society of Medical Microbiology.
- Track 13-1Virus Safety Risk Assessment
- Track 13-2Virus Clearance Technologies
- Track 13-3Latest Developments in the Prophylactic and the Therapeutic Segment
- Track 13-4Future Potential of the Vaccine Market
- Track 13-5Optimizing Pre-clinical & Clinical Trials Performance
The global market for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% between 2012 and 2017. A new report by visiongain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015.
- Track 14-1Approaches by life cycle stage
- Track 14-2Gene delivery
- Track 14-3Protein manufacturing
- Track 14-4Human monoclonal antibody isolation
- Track 14-5High-throughput sequencing
- Track 14-6Structure-based vaccine design
The global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.
Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem cell therapy, but some therapies derived from umbilical cord blood are also in use.
- Track 15-1Stem cell therapy for viral infections: promises and challenges
- Track 15-2Strain identification assays and rapid diagnostic testing for viral infections
- Track 15-3New strategies to combat flu viruses
- Track 15-4Latest Developments in the Prophylactic and the Therapeutic Segment
- Track 21-1Molecular Diagnosis, Immunology and Vaccines development
- Track 21-2Host-Virus Interactions and Pathogenesis and Prion Disease
- Track 21-3Emerging Viruses and Zoonosis Epidemiology